Industry News
Compelling data with STAR0602 demonstrates potent, single agent anti-tumor activity in PD-1 refractory solid tumor models Distinct mechanism of action through expansion of a subset of Vβ T cells with a novel memory phenotype that promotes durable de novo antitumor immune responses STAR0602 slated to initiate Phase 1/2 clinical trial (START-001) in the fourth quarter…
Read More
– Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design – Excerpt from the Press Release: BEDFORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a presentation on the design of pheEDIT, a Phase 1, open-label, dose-escalation study evaluating one-time…
Read More
Molecular Real-World Data (RWD) from 3,000+ individuals with advanced and metastatic urothelial cancer highlight Peroxisome Proliferator-Activated Receptor Gamma (PPARG) as a lineage defining transcription factor is foundational to Flare’s precision oncology approach Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other…
Read More
– Mean body weight loss of 11.1% in participants receiving once-weekly injections of 2.4 mg XW003 for 18 weeks – 88.5% and 57.7% of participants receiving 2.4 mg XW003 for 18 weeks achieved weight loss of ≥5% and ≥10%, respectively – XW003 was safe and well tolerated, with an adverse event profile consistent with other…
Read More
Addition of a cross-ancestry polygenic risk score to the standard of care clinical risk predictor tool improved breast cancer risk assessment across multiple ancestries Excerpt from the Press Release: MENLO PARK, Calif., Oct. 27, 2022 /PRNewswire/ — MyOme, a clinical whole genome platform analysis company, today announced new data on its cross-ancestry integrated risk score…
Read More
OTX-2002 is the First-Ever Epigenomic Controller in a New Class of Programmable mRNA Therapeutics to be Administered to Patients Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (NASDAQ: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines, today announced…
Read More
– MCLA-129 observed to be well tolerated with a favorable safety profile – Antitumor activity was observed among heavily pretreated patients, across multiple tumor types and dose levels – Initial recommended phase 2 dose 1500 mg every two weeks; expansion cohorts enrolling – Investor call to discuss a MCLA-129 program update on October 26 at 13:30…
Read More
A tool for reconstruction of a 3D model of the knee from 2D X-ray images is being evaluated on clinical data at a leading medical center with promising results Excerpt from the Press Release: TEL AVIV, Israel and SAN JOSE, Calif., Oct. 27, 2022 /PRNewswire/ — RSIP Vision, an experienced developer of groundbreaking AI technologies for…
Read More
COVALENT-101 now includes patients with relapsed/refractory (R/R) CLL BMF-219 is the first menin inhibitor in the clinic for CLL Preclinical data presented at ASCO 2022 demonstrated the potency of BMF-219, a covalent menin inhibitor, across varying cytogenetic risk profiles and Rai stages, indicating broad activity with over 98% cell lethality in these CLL models at…
Read More
NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist Excerpt from the Press Release: SAN DIEGO, Oct. 27, 2022 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound…
Read More